Thymidine Kinase 1 (TK1) is a key enzyme in DNA synthesis and it is produced by and released into the blood from proliferating cells, especially tumor cells. It is a well-studied biomarker for studying tumor growth.
TK1 levels in the blood of healthy subjects are very low, requiring sensitive assays. When developing such assays, establishing the zero calibrator, or blank, value is a key point as it determines the limit of sensitivity.
ArOCell has redesigned the preparation of the zero Calibrator in its TK 210 ELISA kit, replacing the current human serum based material with a proprietary buffer-based Calibrator. The benefit of the change is better discrimination of TK1 values in samples with low-normal values. The performance of the Arocell TK 210 ELISA with the new zero calibrator in healthy subjects will be presented by Dr. Kiran Kumar Jagarlamudi, clinical research manager at AroCell at the annual meeting of the International Society of Oncology and Biomarkers (ISOBM) in Chicago next month, September 4th.
We are pleased that we have improved the TK 210 ELISA, but one should keep in mind that establishment of the value of this increased sensitivity and discrimination will require further studies including material from subjects with known pathologies says Jan Stålemark, CEO at AroCell.
For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please seewww.arocell.com. This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through Jan Stålemark, at 16:58 CET on 12 August 2016. Redeye is AroCell:s Certified Adviser.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AroCell AB via Globenewswire